Oculis Holding AG

NASDAQ:OCS

Biotechnology

Healthcare
$7.39 -2.43%

-$0.28 today

Market cap
$456.20M
Beta
0.13
P/E (TTM)
-5.5
EPS (TTM)
-$1.61
52W Low $10.52High $34.48

Volume 0.31M

Average 0.65M

OCS Net Income

Bottom-line profit after all expenses, interest, and taxes.

Oculis Holding AGNASDAQ: OCS

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income remains negative

Q1 FY2026 net income was -CHF 29.5M, compared with -CHF 33.21M a year earlier. Trailing-twelve-month net income was -CHF 95.06M.

Context

  • Net income grew in size in 2 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 5 analysts of -CHF 74.81M (+20.8%) for the fiscal year ending Dec 2026, a step up from the -10.2% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-CHF 29.5M-26.4% QoQ
Last fiscal yearDec 2025
-CHF 94.51M-10.2% YoY
LTMMar 2026
-CHF 95.06M+7.6% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+11.2%+6.0%-5.2 pp
1 year-10.2%+20.8%+31.0 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

CHF · from the income statement

Latest · FY2025
(94.51M) CHF
Year-over-year change
-10.2%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How OCS compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +7.6% is the 3rd highest of 6, against a peer median of -50.7%.
  • Net income amounts to 18861.3% of revenue for OCS, versus a peer median of 2062.4%.
OCS Competitors
Net Income for OCS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
OKYOOKYO Pharma LimitedFY2025-$4.71M USD+72.0%——
HROWHarrow Health, Inc.LTM Mar 2026-$14.96M USD+31.0%—5.6%
OTLKOutlook Therapeutics, Inc.LTM Mar 2026-$60.96M USD-388.6%—18297.5%
OCSOculis Holding AGLTM Mar 2026-CHF 95.06M CHF+7.6%—18861.3%
EYPTEyePoint Pharmaceuticals, Inc.LTM Mar 2026-$271.6M USD-85.0%—3566.6%
OCULOcular Therapeutix, Inc.LTM Mar 2026-$290.5M USD-50.7%—558.2%
Peer median (excluding OCS) —-50.7%—2062.4%

Competitors are the stored peer set for OCS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

CHF
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue000686K0
Cost of Revenue00052.08M0
Gross Profit000(51.4M)0
Gross Margin———-7492.3%—
Research & Development9.57M22.22M29.25M52.08M54.52M
Selling, General & Admin4.1M6.74M14.72M21.81M24.63M
Operating Expenses13.23M32.38M80.71M21.81M79.15M
Depreciation & Amortization235K299K287K406K521.45K
EBITDA(13.17M)(31.9M)(87.09M)(85.53M)(93.37M)
EBITDA Margin———-12468.1%—
Operating Income(13.23M)(32.38M)(80.71M)(73.2M)(79.15M)
Operating Margin———-10671.1%—
Interest Income21K126K1.59M2.17M1.69M
Interest Expense5.12M6.44M1.46M639K795.55K
Other Income / Expenses(5.29M)(6.27M)(7.98M)(12.73M)(15.54M)
Income Before Tax(18.52M)(38.64M)(88.7M)(85.94M)(94.69M)
Pre-Tax Margin———-12527.3%—
Income Tax Expense27K55K107K(160K)177.64K
Net Income(18.55M)(38.7M)(88.8M)(85.78M)(94.51M)
Net Margin———-12503.9%—
EPS (Basic)(0.57)(1.18)(2.97)(2.12)(1.81)
EPS (Diluted)(0.57)(1.18)(2.97)(2.12)(1.81)
Weighted Avg Shares32.73M32.73M29.9M40.41M52.36M
Weighted Avg Shares (Diluted)32.73M32.73M29.9M40.41M52.36M

Oculis Holding AG

NASDAQ:OCS

Intrinsic Alpha fair value

Locked

Current Price

$7.39

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.